Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol

Fabiana Coelho Inouye, Vivien Teo, Jessie Clarke, Sofia Georgopoulou, Ana Maria Rosa Freato Gonçalves, Lorena Lôbo de Figueiredo-Pontes, Leonardo Régis Leira Pereira, Sarah Chapman · 2026

Read Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol by Fabiana Coelho Inouye, Vivien Teo, Jessie Clarke, Sofia Georgopoulou, Ana Maria Rosa Freato Gonçalves, Lorena Lôbo de Figueiredo-Pontes, Leonardo Régis Leira Pereira, Sarah Chapman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0358485.txt.

Description

Fabiana Coelho Inouye led a team of eight authors who published a study protocol in PLOS ONE in 2026. Their topic was why some blood cancer patients do not take their daily kinase-blocking pills as directed. The cancers in view are the classic slow-growing types grouped as myeloproliferative neoplasms.

Inouye's group set out a plan for a review that mixes numbers with interviews and open-ended data. They focus on causes of poor adherence that can actually be changed, such as side effects, cost, or weak support. Mapping those causes first is what allows clinics to design help that keeps patients on drugs that control their disease.

Catalog record

CREATORFabiana Coelho Inouye, Vivien Teo, Jessie Clarke, Sofia Georgopoulou, Ana Maria Rosa Freato Gonçalves, Lorena Lôbo de Figueiredo-Pontes, Leonardo Régis Leira Pereira, Sarah Chapman
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32351
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0358485

Browse the full library · About the Tower of Babel